Bone Marrow Microenvironment as a Source of New Drug Targets for the Treatment of Acute Myeloid Leukaemia.
Kathryn A SkeldingDaniel L BarryDanielle Z TheronLisa F LinczPublished in: International journal of molecular sciences (2022)
Acute myeloid leukaemia (AML) is a heterogeneous disease with one of the worst survival rates of all cancers. The bone marrow microenvironment is increasingly being recognised as an important mediator of AML chemoresistance and relapse, supporting leukaemia stem cell survival through interactions among stromal, haematopoietic progenitor and leukaemic cells. Traditional therapies targeting leukaemic cells have failed to improve long term survival rates, and as such, the bone marrow niche has become a promising new source of potential therapeutic targets, particularly for relapsed and refractory AML. This review briefly discusses the role of the bone marrow microenvironment in AML development and progression, and as a source of novel therapeutic targets for AML. The main focus of this review is on drugs that modulate/target this bone marrow microenvironment and have been examined in in vivo models or clinically.
Keyphrases
- bone marrow
- acute myeloid leukemia
- mesenchymal stem cells
- stem cells
- induced apoptosis
- allogeneic hematopoietic stem cell transplantation
- liver failure
- drug induced
- respiratory failure
- acute lymphoblastic leukemia
- oxidative stress
- emergency department
- intensive care unit
- aortic dissection
- immune response
- cell proliferation
- multiple myeloma
- extracorporeal membrane oxygenation
- hepatitis b virus
- cancer stem cells
- adverse drug
- replacement therapy
- acute respiratory distress syndrome
- mechanical ventilation